GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » SunWay Biotech Co Ltd (ROCO:1271) » Definitions » Net Income From Continuing Operations

SunWay Biotech Co (ROCO:1271) Net Income From Continuing Operations : NT$142.1 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SunWay Biotech Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. SunWay Biotech Co's net income from continuing operations for the six months ended in Dec. 2024 was NT$57.5 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was NT$142.1 Mil.

SunWay Biotech Co Net Income From Continuing Operations Historical Data

The historical data trend for SunWay Biotech Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SunWay Biotech Co Net Income From Continuing Operations Chart

SunWay Biotech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial 125.70 170.21 39.63 56.23 142.09

SunWay Biotech Co Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.83 20.22 36.02 84.60 57.49

SunWay Biotech Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$142.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SunWay Biotech Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » SunWay Biotech Co Ltd (ROCO:1271) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:8905 TPE:1233 ROCO:6968 TPE:1220 ROCO:2756 ROCO:1294 ROCO:4109 ROCO:6929 ROCO:6886 TPE:1219 XSWX:NESN XPAR:BN SHSE:603288 KHC GIS K NSE:NESTLEIND SHSE:600887 TSE:2802 SZSE:300999
Traded in Other Exchanges
N/A
Address
No. 139, Xing’ai Road, Neihu District, Taipei, TWN, 11494
Website
http://www.sunway.cc
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.

SunWay Biotech Co Headlines

No Headlines